Cholangitis is a condition that happens when your bile ducts become inflamed or infected. The bile ducts are thin tubes that ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...

Primary billiary cholangitis, or PBC, is a chronic disease that gradually damages the bile ducts, and eventually your liver. You may also hear it called primary billiary cirrhosis. Your bile ducts ...

Obeticholic acid had been awarded accelerated approval by the FDA in May 2016 as a second-line treatment for PBC patients not ...

Primary sclerosing cholangitis (PSC) is a chronic autoimmune disease with inflammation and stricture formation in the bile ducts inside the liver and/or in the extrahepatic bile duct which drains into ...

Single cases of AIH and autoimmune cholangitis (antimitochondrial antibody-negative PBC) overlap have also been reported. Empiric medical treatment of AIH-PBC and AIH-PSC overlap syndromes ...

The global market for primary sclerosing cholangitis (PSC) is on an impressive growth trajectory, with forecasts estimating a ...

The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...

Ipsen (IPSEY) announced the European Commission has conditionally approved Iqirvo 80mg tablets for the treatment of primary biliary ...

Researchers discovered that IBD significantly increases the risk of developing T1D, and this association works both ways, ...

The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) met today to discuss ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...